About Us

Elixie is an Israeli biotech company established in 2019 by experienced entrepreneurs to invent, develop, invest, and commercialize Med-Tech technologies. Our mission is to unlock traditional plant medicines' enormous potential. Our goal is to utilize novel drug delivery systems to create advanced combination products that connect traditional wisdom with updated scientific tools and techniques.

Elixie holds headquarters in both Tel Aviv and an R&D lab at the Hebrew University of Jerusalem. Our lab collaborates with pre-clinical and clinical sites to provide cutting-edge scientific research that helps generate genuinely innovative products. We believe in collaborations and partnerships with research institutes, entrepreneurs, activists, governments, industry, and business entities. Everyone who wishes to participate in the mission we pursue, progressing human health and quality of life, is a potential partner!

Meet the Team


Scientific Board of Advisory


Prof. Abraham Domb

Medicinal Chemistry & Biopolymers

  • Chief Scientist of the Ministry of Science and Technology
    of Israel.

  • Former Head of The School of Pharmacy at the Hebrew University of Jerusalem.

  • Head of HUJI’s Biopolymer and Pharmaceutical Chemistry Laboratories at the Multidisciplinary Center on Cannabinoid Research at the Hebrew University of Jerusalem.

Prof. Domb’s research has generated over 700 scientific publications, cited in over 40,000 publications, and resulted in several products and companies, including Gliadel, Bioprotect, Canker Cover, OraMiost, and Deximun.


Prof. Amnon Hoffman

Bio-Pharmacy & Clinical Pharmacy

  • Head of the National Council of Pharmacy of Israel.

  • Head of the Biopharmaceutics of Drug Delivery Systems Laboratory at the Multidisciplinary Center on Cannabinoid Research at the Hebrew University of Jerusalem.

Manager of the Doctor of Pharmacy program in the Faculty of Medicine at HUJI. For 26 years, Prof. Hoffman has served as the Head of the Division of Clinical Pharmacy at HUJI. Prof. Hoffman has published over 160 scientific publications, been cited in over 9,000 publications, and holds over 20 patents in drug delivery systems (DDS) and drug discovery.

Our Partners